Expected Moves

Hansa Biopharma reports Q3 2026 results with a critical focus on revenue trajectory and operating cash burn reduction from current levels.

Management provides status updates on late-stage clinical trials and regulatory milestones heading into 2027.

Full-year results and crucial FY2027 forward guidance, particularly regarding operational runway, commercial growth, and debt servicing.

High probability of equity dilution, convertible debt issuance, or strategic restructuring given dwindling cash reserves.